170 related articles for article (PubMed ID: 38205741)
1. Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers.
Thorlund K; Duffield S; Popat S; Ramagopalan S; Gupta A; Hsu G; Arora P; Subbiah V
J Comp Eff Res; 2024 Mar; 13(3):e230147. PubMed ID: 38205741
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls.
Gray C; Ralphs E; Fox MP; Lash TL; Liu G; Kou TD; Rivera DR; Bosco J; Braun KVN; Grimson F; Layton D
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5796. PubMed ID: 38680093
[TBL] [Abstract][Full Text] [Related]
4. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
Popat S; Liu SV; Scheuer N; Hsu GG; Lockhart A; Ramagopalan SV; Griesinger F; Subbiah V
Nat Commun; 2022 Jun; 13(1):3500. PubMed ID: 35715405
[TBL] [Abstract][Full Text] [Related]
5. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.
Struebing A; McKibbon C; Ruan H; Mackay E; Dennis N; Velummailum R; He P; Tanaka Y; Xiong Y; Springford A; Rosenlund M
J Comp Eff Res; 2024 May; 13(5):e230175. PubMed ID: 38573331
[No Abstract] [Full Text] [Related]
6. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
[TBL] [Abstract][Full Text] [Related]
7. Quantitative bias analysis in practice: review of software for regression with unmeasured confounding.
Kawabata E; Tilling K; Groenwold RHH; Hughes RA
BMC Med Res Methodol; 2023 May; 23(1):111. PubMed ID: 37142961
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. The role of quantitative bias analysis for nonrandomized comparisons in health technology assessment: recommendations from an expert workshop.
Leahy TP; Durand-Zaleski I; Sampietro-Colom L; Kent S; Zöllner Y; Coyle D; Casadei G
Int J Technol Assess Health Care; 2023 Nov; 39(1):e68. PubMed ID: 37981828
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
14. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
15. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
17. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
18. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
[TBL] [Abstract][Full Text] [Related]
19. Application of quantitative bias analysis for unmeasured confounding in cost-effectiveness modelling.
Leahy TP; Duffield S; Kent S; Sammon C; Tzelis D; Ray J; Groenwold RH; Gomes M; Ramagopalan S; Grieve R
J Comp Eff Res; 2022 Aug; 11(12):861-870. PubMed ID: 35678168
[TBL] [Abstract][Full Text] [Related]
20. A meta-analytic framework to adjust for bias in external control studies.
Incerti D; Bretscher MT; Lin R; Harbron C
Pharm Stat; 2023 Jan; 22(1):162-180. PubMed ID: 36193866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
